91 related articles for article (PubMed ID: 23830351)
41. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.
Lothe RA; Smith-Sørensen B; Hektoen M; Stenwig AE; Mandahl N; Saeter G; Mertens F
Genes Chromosomes Cancer; 2001 Feb; 30(2):202-6. PubMed ID: 11135438
[TBL] [Abstract][Full Text] [Related]
42. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
[TBL] [Abstract][Full Text] [Related]
43. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.
Holtkamp N; Mautner VF; Friedrich RE; Harder A; Hartmann C; Theallier-Janko A; Hoffmann KT; von Deimling A
Acta Neuropathol; 2004 Feb; 107(2):159-68. PubMed ID: 14673600
[TBL] [Abstract][Full Text] [Related]
44. Primary malignant peripheral nerve sheath tumor of the cauda equina with metastasis to the brain in a child: case report and literature review.
Xu Q; Xing B; Huang X; Wang R; Li Y; Yang Z
Spine J; 2012 Apr; 12(4):e7-13. PubMed ID: 22521675
[TBL] [Abstract][Full Text] [Related]
45. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos M; Vielh P; Soria JC; Andre F
J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
[TBL] [Abstract][Full Text] [Related]
46. Chemically induced rat Schwann cell neoplasia as a model for early-stage human peripheral nerve sheath tumors: phenotypic characteristics and dysregulated gene expression.
Koelsch B; van den Berg L; Grabellus F; Fischer C; Kutritz A; Kindler-Röhrborn A
J Neuropathol Exp Neurol; 2013 May; 72(5):404-15. PubMed ID: 23584200
[TBL] [Abstract][Full Text] [Related]
47. Malignant peripheral nerve sheath tumors: an update.
Fuchs B; Spinner RJ; Rock MG
J Surg Orthop Adv; 2005; 14(4):168-74. PubMed ID: 16442014
[TBL] [Abstract][Full Text] [Related]
48. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
49. Highly aneuploid zebrafish malignant peripheral nerve sheath tumors have genetic alterations similar to human cancers.
Zhang G; Hoersch S; Amsterdam A; Whittaker CA; Lees JA; Hopkins N
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16940-5. PubMed ID: 20837522
[TBL] [Abstract][Full Text] [Related]
50. Genomic medicine and targeted therapy for solid tumors.
Stevens EA; Rodriguez CP
J Surg Oncol; 2015 Jan; 111(1):38-42. PubMed ID: 25042935
[TBL] [Abstract][Full Text] [Related]
51. Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery.
Schubert M; Iorio F
Pharmacogenomics; 2014 Dec; 15(16):1943-6. PubMed ID: 25521353
[No Abstract] [Full Text] [Related]
52. Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor.
Ivanisevic T; Steklov M; Lechat B; Cawthorne C; Gsell W; Velde GV; Deroose C; Van Laere K; Himmelreich U; Sewduth RN; Sablina AA
Cancer Commun (Lond); 2023 Dec; 43(12):1386-1390. PubMed ID: 37890861
[No Abstract] [Full Text] [Related]
53. Editor's Note: Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment.
Yang J; Ylipää A; Sun Y; Zheng H; Chen K; Nykter M; Trent J; Ratner N; Lev DC; Zhang W
Clin Cancer Res; 2019 May; 25(10):3195. PubMed ID: 31092619
[No Abstract] [Full Text] [Related]
54. Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.
Du X; Yang J; Ylipää A; Zhu Z
J Hematol Oncol; 2022 Oct; 15(1):158. PubMed ID: 36303190
[No Abstract] [Full Text] [Related]
55. Impact of chromosomal translocation and genomic instability on personalized medicine.
Chen Z; Wang JH
Per Med; 2013 Mar; 10(2):111-114. PubMed ID: 29758842
[No Abstract] [Full Text] [Related]
56. Malignant peripheral nerve sheath tumors.
Farid M; Demicco EG; Garcia R; Ahn L; Merola PR; Cioffi A; Maki RG
Oncologist; 2014 Feb; 19(2):193-201. PubMed ID: 24470531
[TBL] [Abstract][Full Text] [Related]
57. Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.
Hirbe AC; Dahiya S; Miller CA; Li T; Fulton RS; Zhang X; McDonald S; DeSchryver K; Duncavage EJ; Walrath J; Reilly KM; Abel HJ; Pekmezci M; Perry A; Ley TJ; Gutmann DH
Clin Cancer Res; 2015 Sep; 21(18):4201-11. PubMed ID: 25925892
[TBL] [Abstract][Full Text] [Related]
58. The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.
Nelson CB; Rogers S; Roychoudhury K; Tan YS; Atkinson CJ; Sobinoff AP; Tomlinson CG; Hsu A; Lu R; Dray E; Haber M; Fletcher JI; Cesare AJ; Hegde RS; Pickett HA
Nat Commun; 2024 Feb; 15(1):1385. PubMed ID: 38360978
[TBL] [Abstract][Full Text] [Related]
59. HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas.
Zhu H; Tan J; Pan X; Ouyang H; Zhang Z; Li M; Zhao Y
BMC Cancer; 2023 Feb; 23(1):125. PubMed ID: 36750807
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
